Endra Life Sciences announces favorable TAEUS liver device study results

Endra Life Sciences (NDRA) announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS Liver device. “While MRI-PDFF remains the gold standard for liver fat quantification, its high cost and limited availability create significant barriers for the more than two billion people afflicted by MASLD,” said Alexander Tokman, CEO of Endra Life Sciences. “These new performance data showing a 3.3% SEM and a 0.89 ICC strongly support our belief that TAEUS can deliver consistent results similar to an MRI, but at the point of patient care and at a much lower cost. This addresses a critical need for clinicians and pharmaceutical companies that require a diagnostic tool to monitor treatment frequently and affordably.”